Taizhou-based BioPerfectus Technologies, a high-tech enterprise specializing in molecular diagnostics, was ranked 74th in the 2022 China Top 100 Pharmaceutical Industry Rankings.
The company's debut on the prestigious list has been hailed as a reflection of its innovation capability, development potential, and technological prowess.
Focused on infectious disease testing and maternal-child health, BioPerfectus Technologies has developed integrated solutions encompassing diagnostic reagents and instruments. With a core strength in molecular diagnostics, the company has been expanding its applications, diversifying its product portfolio, and actively exploring international markets through global collaborations.
Driven by its commitment to innovation, BioPerfectus Technologies had secured registration certificates for three products this year: Malaria Parasite Antigen Test Kit (Colloidal Gold Method), EB Virus Nucleic Acid Test Kit (Fluorescent PCR Method), and Norovirus Nucleic Acid Test Kit (Fluorescent PCR Method).
In a move into renal function indicators, BioPerfectus Technologies has obtained registration certificates for three immunological quantitative detection products: Cystatin C Determination Reagent Kit, β2-Microglobulin Determination Reagent Kit, and Urine Microalbumin Determination Reagent Kit (Fluorescent Immunochromatography Method).
Three other Taizhou-based pharmaceutical enterprises also made the rankings: Yangtze River Pharmaceutical Group (10th), Jumpcan Pharmaceutical Group Co Ltd (35th), and Suzhong Pharma Group (98th).